Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension

Cardiology in Review

Volumn 16, Issue 2, 2008, Pages 95-108

  Han, Jung A ^a   Frishman, William H ^b,c   Wu Sun, Sung ^a   Palmiero, Pat Michael ^b   Petrillo, Richard ^a  

^a Mount Vernon Hospital USA   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antiglaucoma treatment; Glaucoma; Intraocular pressure; Ocular hypertension

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; CARBACHOL; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; ECOTHIOPATE IODIDE; GLYCEROL; LATANOPROST; LEVOBUNOLOL; MANNITOL; METHAZOLAMIDE; METIPRANOLOL; PILOCARPINE; PLACEBO; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER; UREA;

ASTHMA; BRADYCARDIA; CARDIOTOXICITY; DRUG MECHANISM; GLAUCOMA; HEART ARRHYTHMIA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PATIENT CARE; RESPIRATORY DISTRESS; REVIEW;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; GLAUCOMA; HEART DISEASES; HEART RATE; HUMANS; OCULAR HYPERTENSION;

EID: 39449096436     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318156ec64     Document Type: Review

References (169)

1. Glaucoma Research Foundation [Web site]. Available at: www.glaucoma.org. Accessed January 2007.
2. Alward WLM. Medical management of glaucoma. N Eng J Med. 1998;339:1298-1307.
3. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22:1-21.
4. Barber BL, Santanello NC. Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. Int J Clin Pharmacol Ther. 1995;22:598-604.
5. Frishman WH, Kowalski M, Nagnur S, et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on β-adrenergic blockade. Heart Dis. 2001;3:386-397.
6. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypotensive agent. Br J Ophthalmol. 1967;51:222-226.
7. Bucci MG, Missiroli A, Pecori-Giraldi J, et al. Local administration of propranolol in the treatment of glaucoma. Boll Ocul. 1968;47:51-60.
8. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305:500-506.
9. Novack GD. Ophthalmic beta blockers since timolol. Surv Ophthalmol. 1987;31:307-327.
10. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surg Ophthalmol. 1982;26:207-218.
11. Lewis PR, Phillips TG, Sassani JW. Topical therapies for glaucoma: what family physicians need to know. Am Fam Physician. 1999;59:1871-1879, 1882.
12. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging. 1997;11:352-360.
13. Hoffman BB, Lefkowitz RJ. Adrenergic receptor antagonists. In: Gilman AG, Rall TW, Niew AS, et al, eds. Goodman and Gilman's the Pharmacologic Basic of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:199-248.
14. Frishman WH, Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs. II. Physiologic and metabolic effects. Am Heart J. 1979;97:797-807.
15. Mirza GE, Karakucuk S, Tamel E. Comparision of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J Glaucoma. 2000;9:45-50.
16. Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Surv Ophthalmol. 1990;35:205-218.
17. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic β-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J Clin Pharmacol. 1994;34:795-803.
18. Polansky JR. Beta-adrenergic therapy for glaucoma. Int J Ophthalmol Clin. 1990;30:219-229.
19. Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Phychopharmacol. 1987;7:264-267.
20. Fraunfelder FT, Meyers SM. Systemic adverse reactions to glaucoma medications. Int Ophthalmol Clin. 1989;29:143-146.
21. Brooks AMV, Gillies WE. Ocular β blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging. 1992;2:208-221.
22. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749-760.
23. Frishman WH. Alpha- and beta-adrenergic blocking drugs. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill; 2003:67-97.
24. Hughes FC. Clinical studies of systemic effects of topical β blockers. Int Ophthalmol Clin. 1989;29:s19-s20.
25. Ballintine EJ, Garner LL. Improvement of the coefficient of outflow in glaucomatous eyes. Prolonged local treatment with epinephrine. Arch Ophthalmol. 1961;66:314-317.
26. Neufeld AH, Bartels SP. Receptor mechanisms for epinephrine and timolol. In: Lutjen-Drecoll E, ed. Basic Aspects of Glaucoma Research. Stuttgart, Germany: Schattauer; 1982:113-122.
27. Nilsson FE, Maepea O, Samuelsson M, et al. Effects of timolol on terbutaline and VIP-stimulated aqueous humor flow in the cynomolgus monkey. Curr Eye Res. 1990;9:863-872.
28. Lutjen-Drecoll E, Kaufman P, Eichhorn M. Long-term timolol and epinephrine in monkeys. I. Functional morphology of ciliary processes. Trans Ophthalmol Soc U K. 1986;105:180-195.
29. Cherksey BD, Alvarado JA, Polansky JR. Ion channel activity of ciliary process epithelium vesicles reconstituted into planar bilayers. Invest Ophthalmol Vis Sci. 1988;29(Suppl):175-207.
30. Arend O, Harris A, Arend S, et al. The acute effect of topical beta-adrenoreceptor blocking agents on retinal and optic nerve head circulation. Acta Ophthlmol Scand. 1998;76:43-49.
31. Turacli ME, Ozden RG, Gurses MA. The effect of betaxolol on ocular blood flow and visual fields in patients with normotensive glaucoma. Eur J Ophthalmol. 1998;8:62-66.
32. Collignon NJ, Collignon-Brach JD. Effect of topical beta blockers on human retinal vessels diameters. Int Ophthalmol. 1997;21:199-203.
33. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med. 1986;104:197-199.
34. Berson FG, Epstein DL. Separate and combined effects of timolol maleate and acetazolamide in open angle glaucoma. Am J Ophthalmol. 1981;92:788-791.
35. Schenker H, Yablonski ME, Podos SM, et al. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99:1212-1216.
36. Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. Invest Ophthalmol Visc Sci. 1978;17:293-296.
37. Uusitalo RJ, Palkama A. Long-term evaluation of timolol. Acta Ophthalmol. 1989;67:573-581.
38. Tipping R; Timoptic-XE 0.5% Study Group. Shedden A, Laurence J, Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther. 2001;23:440-450.
39. Walters TR, Maloney S, Slater D, et al. Efficacy and tolerability of 0.5% timolol maleate gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension. Clin Ther. 1998;20:1170-1178.
40. Sadiq SA, Vernon SA. Sublingual timolol - an alternative to topical medication in glaucoma? Br J Ophthalmol. 1996;80:532-535.
41. Linkewich JA, Herling IM. Bradycardia and congestive heart failure associated with ocular timolol maleate. Am J Hosp Pharm. 1981;38:699-701.
42. Nelson WL, Fraunfeld FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol. 1986;102:606-611.
43. Treseder AS, Thomas TPL. Sinus arrest due to timolol eye drops. Br J Clin Pract. 1986;40:256-258.
44. Odeh M, Oliven A, Bassan H. Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract. 1991;32:97-98.
45. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardio-respiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84:710-713.
46. Zimmerman TJ, Leader BJ, Golob DS. Potential side effects of timolol therapy in the treatment of glaucoma. Ann Ophthalmol. 1981;13:683-689.
47. Joyce PW, Raj PS. Topical beta blockers and serum lipoproteins. Br J Ophthalmol. 1991;75:510-511.
48. Kaiserman I, Kaiserman N, Elhayany A, et al. Topical beta-blockers are not associated with an increased risk of treatment for depression. Ophthalmology. 2006;113:1077-1080.
49. Hayreh SS, Podhajsly P, Zimmerman MB. Beta blocker eyedrops and nocturnal arterial hypotension. Am J ophthalmol. 1999;128:301-309.
50. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917-2923.
51. Wagenvoort AM, Van Vugt JMG, Sobotka M, et al. Topical therapy in pregnancy. Is it safe for the fetus? Teratology. 1998;58:258-262.
52. Stewart WC, Dubiner HB, Mundorf TK, et al. Effects of carteolol and timolol on plamsa lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol. 1999;127:142-147.
53. Bartlett JD, Olivier M, Richardson T, et al. Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. J Glaucoma. 1999;8:388-395.
54. Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. Br Med J (Clin Res Ed). 1987;294:155-156.
55. Valuck RJ, Perlman JI, Anderson C, et al. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depreesion among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf. 2001;10:511-516.
56. Houde M, Castilloux AM, Tingey D, et al. Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. Can J Ophthalmol. 2003;38:469-475.
57. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113:1069-1076.
58. Van Der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185.
59. Buckley MM-T, Goa KL, Clissold SP. Ocular betaxolol: a review of its pharmacological properties and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990;40:75-90.
60. Erkin EF, Celik P, Kayikcioglu O, et al. Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. Ophthalmologica. 2006;220:332-337.
61. Harris LS, Greenstein SU, Bloom AF. Respiratory difficulties with betaxolol. Am J Ophthalmol. 1986;102:274-275.
62. Engel G. Subclasses of beta-adrenoceptors, a quantitative estimation of beta1 and beta2-adrenoceptors in guinea pig and human lung. Postgrad Med J. 1981;57(Suppl 1):77-83.
63. Lesar TS. Comparison of ophthalmic β blocking agents. Clin Pharmacol. 1987;6:451-463.
64. Polansky JR, Alvarado JA. Isolation and evaluation of target cells in glaucoma research: hormone receptors and drug responses. Curr Eye Res. 1985;4:267-279.
65. Caldwell DR, Salisbury CR, Guzeck JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol. 1984;102:539-540.
66. Brooks AMV, Gilles WE, West RH. Betaxolol eye drops as a safe medication to lower intraocular pressure. Aust NZ J Ophthalmol. 1987;15:125-129.
67. Schoene R, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1984;97:86-92.
68. Van Buskirk EM, Weinreb RN, Berry DP, et al. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol. 1986;101:531-534.
69. Diggory P, Cassels BA, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet. 1995;345:1604-1606.
70. Diggory P, Heyworth P, Chau G, et al. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients (see comments). Eye. 1993;7(Pt 5):661-663.
71. Diggory P, Cassels BA, Vail A, et al. Randomized, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol. 1998;82:146-149.
72. Lejeunne C, Munera Y, Hughes F-C. Systemic effects of three β blocker eyedrops: comparison in healthy volunteers of β1- and β2-adrenoceptor inhibition. Clin Pharmacol Ther. 1990;45:578-583.
73. Weinreb RN, Van Buskirk EM, Cherniack R, et al. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol. 1988;106:162-167.
74. Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986. Am J Ophthalmol. 1987;103:592.
75. Yablonski ME, Novack GD, Burke PJ, et al. The effect of levobunolol on aqueous humor dynamics. Exp Eye Res. 1987;44:49-54.
76. The Levobunolol Study Group. Levobunolol: a beta-adrenoceptor antagonist effective in the long-term treatment of glaucoma. Ophthalmology. 1985;92:1271-1276.
77. Afako SK, Thompson JR, Rosenthal AR. A cross-over trial comparing once daily levobunolol with once and twice daily timolol. Eur J Ophthalmol. 1995;5:172-176.
78. The Levobunolol Study Group. Levobunolol: a four year study of efficacy and safety in glaucoma treatment. Ophthalmology. 1989;96:644-645.
79. Geyer O, Lazer M, Novack GD, et al. Levobunolol compared with timolol: a four-year study. Br J Ophthalmol. 1988;892-896.
80. Long DA, Johns GE, Mullen RS, et al. Levobunolol and betaxolol: a double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure. Ophthalmology. 1988;95:735-741.
81. Krieglstein GK, Novack GD, Voepel E, et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. Br J Ophthalmol. 1987;71:250-253.
82. Behrens BW, Kimmich F, Walt JG, et al. A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. Ophthalmologica. 1994;208:32-36.
83. Derick RJ, Robin AL, Tielsch J, et al. Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study. Ophthalmology. 1992;99:424-429.
84. Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology. 1989;96:8-11.
85. Rakofsky SI, Lazar M, Almog Y, et al. Efficacy and safety of oncedaily levobunolol for glaucoma therapy. Can J Ophthalmol. 1989;24:2-6.
86. Silverstone D, Zimmerman T, Choplin N, et al. Evaluation of oncedaily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure. Am J Ophthalmol. 1991;112:56-60.
87. Chun JG, Brodsky MA, Allen BJ. Syncope, bradycardia, and atrioventricular block associated with topical ophthalmic levobunolol. Am Heart J. 1994;127:689-690.
88. Battershill PE, Sorkin EM. Ocular metipranolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1988;36:601-615.
89. Skutta T, Rohmel J. Antiglaucomatous long-term therapy with metipranolol eye drops in 2483 patients (multicenter 12-month study). Zentralblatt Ophthal. 1985;127:398.
90. Denffer H. Efficacy and tolerance of metipranolol: results of a multicenter long-term study. In: Merte HJ, ed. Metipranolol. New York, NY: Springer-Verlag; 1983:121-125.
91. Le Jeunne CL, Hughes FC, Dufier JL, et al. Bronchial and cardiovascular effects of ocular topical β-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol. 1989;29:97-101.
92. Johns MD, Ponte CD. Acute pulmonary edema associated with ocular metipranolol use. Ann Pharnacother. 1995;29:370-373.
93. Melles RB, Wong IG. Metipranolol-associated granulomatous iritis. Am J Ophthalmol. 1994;118:712-715.
94. Patel NP, Patel KH, Moster MR, et al. Metipranolol-associated nongranulomatous anterior uveitis. Am J Ophthalmol. 1997;123:843-844.
95. Chrisp P, Sorkin EM. Ocular carteolol. A review of its pharmacological properties and therapeutic use in glaucoma and ocular hypertension. Drugs Aging. 1992;2:58-77.
96. Araie M, Takase M. Effects of S-596 and carteolol, new beta-adrenergic blockers, and flurbiprofen on the human eye: a fluorophotometric study. Graefes Arch Clin Exp Ophthalmol. 1985;222:259-262.
97. Chrisp P, Sorkin EM. Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging. 1994;4:62.
98. Scoville B, Mueller B, White BG, et al. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol. 1988;105:150-154.
99. Flammer J, Kitazawa Y, Bonomi L, et al. Influence of carteolol and timolol on IOP an visual fields in glaucoma: a multi-center, double-masked, prospective study. Eur J Ophthalmol. 1992;2:169-174.
100. Frishman WH, Covey P. Penbutolol and carteolol: two new beta-adrenergic blockers with partial agonism. J Clin Pharmacol. 1990;30:412-421.
101. Taniguchi T, Kitazawa Y. The potential systemic effects of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol. 1997;8:55-58.
102. DeSantis L, Polansky JR, Bruce L. Relative differences in beta receptor activity between the cardioselective beta blocker, betaxolol, and nonselective beta blockers. In: Proceeding of the XXV International Congress of Ophthalmology, Rome. Amsterdam: Kugler & Ghedini; 1987: 1501-1505.
103. LeJeunne CI, Bringer L, Mondjee-Tahura ZS, et al. Effects cardiovasculaires des collyres au timolol, au carteolol, au metipranolol, au betaxolol chez le suject age. Therapie. 1988;43:89.
104. Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol. 1997;123:465-477.
105. Diggory P, Cassels BA, Fernandez C. Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Age Aging. 1996;25:424-428.
106. Hughes FC, Matte JC, LeJeunne C, et al. Effects of beta-adrenoceptors blocking eye drops in patients with chronic bronchitis. Therapie. 1992;47:211-215.
107. Stewart WC, Shields MB, Allen RC, et al. A 3 month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1991;229:258-261.
108. Grunwald JE, Delehanty J. Effect of topical carteolol on the normal human retinal circulation. Invest Ophthalmol Vis Sci. 1992;33:1853-1856.
109. Yamazaki A, Baba H, Tokoro T. Effects of carteolol and timolol on changes in retinal blood flow: 95th Annual Meeting of the Japanese Society of Ophthalmology. Nippon Ganka Gakkai Zasshi. 1992;96:973.
110. Johnson BF, Danylchuk MA. The relevance of plasma lipid changes with cardiovascular drug therapy. Med Clin North Am. 1989;73:449-473.
111. Coleman AL, Diehl DLC, Henry MD, et al. Topical timolol decreases plasma high-density lipoprotein cholesterol levels. Arch Ophthalmol. 1990;108:1260-1263.
112. Yamamoto T, Kitazawa Y, Noma A, et al. The effects of the beta-adrenergic blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma. 1996;5:252-257.
113. American Medical Association. Mydriatics, Cycloplegics, Local Anesthetics, and Intraocular Miotics. AMA Drug Evaluations. Chicago, IL: American Medical Association; 1995:2249.
114. Strohmaier K, Snyder E, Adamsons I. A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life. J Am Optom Assoc. 1998;69:441-451.
115. Robin AL. Short term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol. 1988;106:912-915.
116. Hurvitz LM, kaufman PL, Robin AL, et al. New developments in the drug treatment of glaucoma. Drugs. 1991;41:514-532.
117. Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Arch Ophthalmol. 1996;114:938-942.
118. Coleman Al, Robin Al, Pollack IP, et al. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol. 1990;108:1264-1267.
119. Robin AL, Coleman AL. Apraclonidine hydrochloride: an evalucation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate. Trans Am Ophthalmol Soc. 1990;88:149-159.
120. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Durgs Aging. 1998;12:225-241.
121. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Goups 1 and 2. Ophthalmology. 2000;17:1171-1177.
122. Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997;10:384-403.
123. Hoyng PFJ, Van Beek LM. Pharmacological therapy for glaucoma. A review. Drugs. 2000;59:411-434.
124. Arend O, Harris A, Wolter P, et al. Evaluation of retinal hemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand. 2003;81:474-479.
125. Fuchsjager-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89:1293-1297.
126. Costagliola C, Campa C, Parmeggiani F, et al. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. Br J Clin Pharmacol. 2007;63:376-379.
127. Centofanti M, Manni GL, Napoli D, et al. Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study. Pharmacol Res. 1997;35:481-485.
128. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):s119-s129.
129. Buclin T, Biollaz J, Lippa EA. Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamine during two weeks ocular administration to normal subjects. Clin Pharmacol Ther. 1991;49:665-673.
130. Gervasoni JP, Lippa EA, Biollaz J. Absence of metabolic effects of methylthienothiopyran 2-sulfonamide, a new carbonic anhydrase inhibitor (CAI) during a 2 week ocular administration. Clin Pharmacol Ther. 1991;49(Suppl):192.
131. Kitazawa Y, Yamamoto T, Azuma I. Effect of MK-50 switch-over from oral carbonic anhydrase inhibitors in primary open-angle glaucoma. Folia Ophthalmol Jpn. 1994;45:914-920.
132. Sabri K, Levin AV. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma. J AAPOS. 2006;10:464-468.
133. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol. 2000;129:136-143.
134. Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol. 1997;42:137-151.
135. Bayer A, Weiler W, Oeverhaus U, et al; Xplore Observation Group. J Ocul Pharmacol Ther. 2004;20:470-478.
136. Linden C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999;14:387-398.
137. Azuma I, Masuda K, Kitazawa Y, et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol. 1993;37:514-525.
138. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566-2573.
139. Larsson LI; European and Canadian Latanoprost Study Group.Pillunat LE, Br J Ophthalmol. 2003;87:1492-1496.
140. Hedner J, Everts B, Moller CS. Latanoprost and respiratory fuction in asthmatic patients: randomized, double-masked, placbo-controlled cross-over evaluation. Arch Ophthalmol. 1999;117:1305-1309.
141. Hedner J, Svedmyr N, Lunde H, et al. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol. 1997;41(Suppl 2):S111-S115.
142. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421-432.
143. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137(Suppl 1):s3-s12.
144. Walters TR, DuBiner HB, Carpenter SP, et al. Bimatoprost Circadian IOP Study Group. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49(Suppl 1):s26-s35.
145. Ota T, Murata H, Sugimoto E, et al. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sic. 2005;46:2006-2011.
146. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185-S202.
147. Weaver AW, Sica DA. Mannitol induced acute renal failure. Nephron. 1987;45:233-235.
148. Oakley DE, Ellis PP. Glycerol and hyperosmolar nonketotic coma. Am J Ophthalmol. 1976;81:469-472.
149. Dalena P, Ferguson W. Adverse effects after glycerol orally and mannitol parenterally. Arch Ophthalmol. 1966;75:201-203.
150. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
151. Lichter PR, Musch DC, Gillespie, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
152. Kass MA, Heuer DK, Higginbotham EJ, et al; The Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
153. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmololgy. 1998;105:1952-1959.
154. Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology. 1997;104:137-142.
155. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group (see comments). Ophthalmology. 1998;105:1936-1944.
156. Henderer JD, Wilson RP, Moster MR, et al. Timolol/Dorzolamide combination therapy as initial treatment for intraocular pressure over 30mmHg. J Glaucoma. 2005;14:267-270.
157. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily cause a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12-16.
158. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899-902.
159. Barnebey H, Orego-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1-7.
160. Katz LJ. Modern alchemy: fixed combinations in glaucoma drugs. Am J Ophthalmol. 2005;140:125-126.
161. Sica DA. Cardiopulmonary effects of ophthalmically administered β-blockers. Congest Heart Fail. 1999;5:81-85.
162. Zimmerman TJ, Kooner KS, Kandarakis AS, et al. Improving therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551-553.
163. Edeki TI, He H, Wood AJJ. Pharmacologic explanation for excessive beta blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA. 1995;274:1611-1613.
164. Ishii Y, Nakamura K, Tsutsumi K, et al. Drug interaction between cimitidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol. 2000;40:193-199.
165. Hewitt AW, Craig JE, Mackey DA. Complex genetics of complex traits: the case of primary open angle glaucoma. Clin Experiment Ophthalmol. 2006;34:472-484
166. Duggal P, Klein AP, Lee KE, et al. Identification of novel genetic loci for intraocular pressure: a genomewide scan of the Beaver Dam Eye Study. Arch Ophthalmol. 2007;125:74-79
167. Rice T, Rankinen T, Province MA, et al. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation. 2000;102:1956-1963
168. Pasquale LR. Genes involved in the pathogenesis of primary openangle glaucoma: in search of the Holy Grail. JAMA. 2007;297:306-307
169. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-609.